VENUS
Enjoy Innovations

VRL/SEC/EXCHANGE

Date:20.07.2026

National Stock Exchange of India Ltd. 5th Floor, Exchange Plaza Bandra (E), **Mumbai- 400 051** **Script Code: VENUSREM**	**BSE Limited** 25th Floor, Phiroze Jeejeebhoy Towers, Dalal Street **Mumbai** **Script Code: 526953**

Sub.: Outcome of Board Meeting date 20th July 2026.

Dear Sir/ Madam,

Pursuant to Reg 30 and other applicable regulations of SEBI LODR and with reference to the communication made on 9th July 2026, the Board of Directors of Venus Remedies Limited ("the Company") at its meeting held on Monday, July 20, 2026 (i.e., today), inter-alia, considered and approved the following:

1. **Financial Results:**

   The Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026, along with the Limited Review Report of the Statutory Auditor in compliance with Regulation 30 and 33 of Listing Regulations. The Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review report are enclosed herewith.

2. **Alteration of Memorandum of Associations of the Company:**

   With reference to the disclosure made by the Company on 26 May 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing the Stock Exchanges regarding the approval by the Board of Directors of the proposed adoption of a revised Memorandum of Association ("MOA") & Articles of Association ("AOA"), subject to the approval of the Members, the Company hereby informs that the Board of Directors, at its meeting held on 20 July 2026, approved certain revisions to the proposed alteration of the MOA.

   The revisions have been proposed primarily to align the Object Clause with the provisions of the Companies Act, 2013 and to update and suitably align the Main Objects and the Objects Incidental or Ancillary to the Attainment of the Main Objects with the Company's current business practices and proposed business activities. The Object Clause has also been updated to explain the business and ancillary objectives of the Company in clearer and more comprehensive terms. The principal business activities of the Company remain unchanged, and the Company continues to operate in the pharmaceutical sector.

VENUS
Enjoy Innovations

The revised MOA incorporating the aforesaid changes shall be placed before the Members for approval by way of a Special Resolution at the ensuing 37th Annual General Meeting of the Company.

The revised details of the proposed amendments are enclosed as **Annexure A**.

Trading window closure

Pursuant to the provisions of Prevention of Insider Trading, the trading window for trading in Company's shares by Designated Persons has been closed from July 01, 2026 till 48 hours from the declaration of financial results.

The Meeting of the Board of Directors of the Company held on 20th July 2026 commenced at 02:45 p.m. and concluded at 06.20p.m.

This intimation is also being uploaded on the Company's website at https://www.venusremedies.com

Thanking you.
Yours faithfully,
for VENUS REMEDIES LIMITED

Neha Neha Digitally signed by Neha Date: 2026.07.20 18:30:53 +05'30'
(Company Secretary)
M. No. F8374

J. K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
S.C.O. 1136-37, SECTOR 22-B, CHANDIGARH - 160 022
0172-270 4536-37 Fax : 0172-270 4537
E-mail : jkjcaps@rediffmail.com

Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Venus Remedies Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

VENUS REMEDIES LIMITED

1. We have reviewed accompanying statement of unaudited standalone financial results of **VENUS REMEDIES LIMITED** ("the Company"), for the Quarter ended 30th June 2026 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement which is responsibility of company's Management has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. The Statement has been approved by the Company's Board of Directors. Our responsibility is to report a conclusion on these statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

J. K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS FRN 004025N CHANDIGARH

5. Emphasis of matter:

1. We draw attention to Note 4 of the accompanying Statement, which describes the outstanding share application money amounting to INR 2,859.72 Lakhs in respect of *Venus Pharma GmbH*, a wholly owned subsidiary of the Company. The share allotment against this amount has been pending as it is not mandatory under the applicable laws of Germany.

   Management has represented that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations carried out by the Management in FY 2026-27. Although the subsidiary is currently facing financial challenges, the Company has reiterated its intention to provide the necessary financial and operational support during the transition period.

Our conclusion is not modified in respect of these matters.

For J.K Jain & Associates
Chartered Accountants
FRN-004025N

J.K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
FRN 004025N
CHANDIGARH

CA Anurag Verma
Partner
M. No. 555033
UDIN: 26555033QFKYXX2548
Date: 20th July, 2026

VENUS®
Enjoy Innovations

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE 2026

(Rs. In Crores except EPS)

S. No.	PARTICULARS	QUARTER ENDED ON			YEAR ENDED ON
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Audited	Unaudited	Audited
1	**Revenue**				
	(a) Revenue from Operations	178.80	259.01	137.13	768.73
	(b) Other Income	2.55	4.64	2.72	11.45
	Total Income	**181.35**	**263.64**	**139.85**	**780.19**
2	**Expenses**				
	(a) Cost of Material Consumed	83.14	116.25	71.33	387.95
	(b) Purchase of stock in trade	1.12	4.73	2.27	10.76
	(c) Changes in Inventories of finished goods, work -in -progress & Stock in Trade	0.02	(1.45)	0.55	(11.47)
	(d) Employee benefits expense	22.56	23.62	19.26	84.85
	(e) Depreciation & amortization expense	6.51	6.50	5.95	24.69
	(f) Selling ,Manufacturing and Administrative expenses	31.17	50.62	22.38	134.28
	(g) Research & Development expenses	4.23	5.80	3.41	18.44
	Total Expense	**148.75**	**206.08**	**125.16**	**649.51**
3	**Profit before taxes (1-2)**	**32.60**	**57.57**	**14.70**	**130.67**
4	**Exceptional Items**	-	-	-	-
5	**Profit after exceptional items (3 + 4)**	**32.60**	**57.57**	**14.70**	**130.67**
	EBIDTA (3+2e)	**39.11**	**64.07**	**20.66**	**155.37**
6	**Tax Expenses**				
A	Current Tax	**8.20**	**14.48**	**3.70**	**32.89**
B	Deferred Tax	**(1.13)**	**(0.37)**	**(0.69)**	**(1.52)**
C	Tax expense related to previous year			-	-
7	**Net Profit /(Loss) for the period (5 - 6)**	**25.53**	**43.45**	**11.70**	**99.31**
8	**Other Comprehensive Income**				
A	(I) Items that will not be reclassified to Profit & loss	**0.03**	**0.38**	**(0.12)**	**0.11**
B	(I) Items that may be reclassified to Profit & loss	**5.89**	**(5.86)**	**3.73**	**0.71**
	(II) Income tax relating to items that may be reclassified to Profit & loss	-			-
C	Total other comprehensive Income Net of Income Tax	**5.92**	**(5.48)**	**3.61**	**0.83**
9	**Total comprehensive Income for the period (7+/-8)**	**31.45**	**37.97**	**15.31**	**100.14**
10	**Paid up equity share capital**	**13.37**	**13.37**	**13.37**	**13.37**
	(Face Value of Equity Shares)	**10**	**10**	**10**	**10**
11	**Other Equity**	-	-	-	**676.26**
12	**Earning per share (of Rs. 10/- each)**				
	(a) Basic (₹)	**19.10**	**32.51**	**8.75**	**74.29**
	(b) Diluted (₹)	**19.10**	**32.51**	**8.75**	**74.29**

J. K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
FRN 004025N
CHANDIGARH

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

VENUS
Enjoy Innovations

Notes to the standalone financial results: -

1. The above Standalone Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 20th July 2026. The statutory auditors of the company have carried out limited review of the above Standalone Financial Result for the quarter ended 30th June 2026, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.

2. The Standalone Financial Results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. The company has a wholly owned subsidiary named Venus Pharma GmbH in Germany and step-down subsidiary of Venus Pharma GmbH named as Venus Pharma Kft in Hungry.

4. The Company's investment in its wholly owned subsidiary, Venus Pharma GmbH, remains pending for formal share allotment, as such allotment is not mandated under the applicable regulations in Germany. The Management considers the investment strategic in nature and, pursuant to the ongoing restructuring of European operations, has engaged a Germany-based financial consultancy firm to advise on the appropriate framework & mechanism.

5. Previous year / period figures have been regrouped/ reclassified wherever necessary.

6. The group has only one reportable segment namely "Pharmaceuticals"

For and on behalf of Board of Directors

for VENUS REMEDIES LIMITED

J. K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
FRN 004025N
CHANDIGARH

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

Pawan Chaudhary

(Managing Director)

Din: 00435503

Date: 20-07-2026

J. K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
S.C.O. 1136-37, SECTOR 22-B, CHANDIGARH - 160 022
0172-270 4536-37 Fax : 0172-270 4537
E-mail : jkjcaps@rediffmail.com

Independent Auditor's Limited Review Report on Unaudited Quarterly Consolidated financial results of Venus Remedies Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To
The Board of Directors
VENUS REMEDIES LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **VENUS REMEDIES LIMITED ("the Holding Company")** and its subsidiary **(collectively referred to as 'the Group')**, for the Quarter ended 30th June 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following Subsidiary:

   i. Venus Pharma Gmbh
   ii. Venus Pharma Kft (Subsidiary of Venus Pharma GmbH)

J. K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS FRN-004025N CHANDIGARH

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the report of referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. **Emphasis of matter**

1. We draw attention to Note 4 of the accompanying Statement, which describes the outstanding share application money amounting to INR 2,859.72 Lakhs in respect of *Venus Pharma GmbH*, a wholly owned subsidiary of the Company. The share allotment against this amount has been pending as it is not mandatory under the applicable laws of Germany.

   Management has represented that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations carried out by the Management in FY 2026-27. Although the subsidiary is currently facing financial challenges, the Company has reiterated its intention to provide the necessary financial and operational support during the transition period.

Our opinion is not modified in respect of above matters.

7. **Other Matter**

The accompanying statement of quarterly unaudited standalone financial results includes the unaudited interim financial results and other financial information in respect of two subsidiaries, whose financial result and other information without giving the effect to the elimination of the intra group transaction reflect groups as:

Name of Subsidiary	Revenue (INR in Crores)	Net Profit/(Loss) (INR in Crores)	Total comprehensive Income (INR in Crores)
Venus Pharma GmbH	2.08	(2.55)	(2.55)
Venus Pharma Kft	Nil	Nil	Nil

J. K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS FRN 004025N CHANDIGARH

Further, subsidiary is located outside India, whose financial results have been prepared in accordance with accounting principles generally accepted in India, and which have been reviewed by us under standard of auditing applicable in India. Our opinion, in so far as it relates to the balances and affairs of the subsidiary, is based on our audit report.

Our conclusion on the Statement is not modified in respect of the above matter.

For J.K Jain & Associates
Chartered Accountants
FRN-004025N

J.K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
FRN 004025N
CHANDIGARH

CA Anurag Verma
Partner
M. No. 555033
UDIN: 26555033DYUPTJ1099
Date: 20th July, 2026

VENUS®
Enjoy Innovations

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(Rs. In Crores except EPS)

S. No.	PARTICULARS	QUARTER ENDED ON			YEAR ENDED ON
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Audited	Unaudited	Audited
1	**Revenue**				
	(a) Revenue from Operations	178.86	259.40	137.18	769.60
	(b) Other Income	2.62	4.95	3.41	12.58
	Total Income	**181.48**	**264.35**	**140.59**	**782.18**
2	**Expenses**				
	(a) Cost of Material Consumed	83.14	116.28	71.33	387.98
	(b) Purchase of stock in trade	1.12	4.73	2.27	10.76
	(c) Changes in Inventories of finished goods, work -in -progress & Stock in Trade	0.02	(1.45)	0.55	(11.47)
	(d) Employee benefits expense	23.37	24.56	20.31	88.68
	(e) Finance Cost	0.00	0.01	0.01	0.04
	(f) Depreciation & amortization expense	6.77	6.76	6.18	25.67
	(g) Selling ,Manufacturing and Administrative expenses	32.35	46.76	23.35	128.20
	(h) Research & Development expenses	4.67	5.10	3.99	18.17
	Total Expense	**151.44**	**202.74**	**127.99**	**648.02**
3	**Profit before taxes (1-2)**	**30.04**	**61.61**	**12.60**	**134.16**
4	**Exceptional Items**	-	-	-	-
5	**Profit after exceptional items (3 + 4)**	**30.04**	**61.61**	**12.60**	**134.16**
	EBIDTA (3+2e+2f)	**36.81**	**68.37**	**18.80**	**159.86**
6	**Tax Expense**				
A	**Current Tax**	**8.20**	**14.48**	**3.70**	**32.89**
B	**Deferred Tax**	**(1.13)**	**(0.37)**	**(0.69)**	**(1.52)**
C	**Tax expense related to previous year**		-	-	-
7	**Net Profit /(Loss) for the period (5 - 6)**	**22.97**	**47.49**	**9.60**	**102.78**
8	**Other Comprehensive Income**				
A	(I) Items that will not be classified to profit & loss	**0.03**	**0.38**	**(0.12)**	**0.11**
B	(I) Foreign Currency Translation Reserve	**(0.01)**	**(0.02)**	**(1.25)**	**(0.82)**
C	(I) Items that will be classified to profit & loss	**5.89**	**(5.86)**	**3.73**	**0.71**
	(II) Income tax relating to items that may be reclassified to Profit & loss	-	-	-	-
	Total other comprehensive Income Net of Income Tax	**5.91**	**(5.49)**	**2.36**	**0.01**
9	**Total comprehensive Income for the period (7+/-8)**	**28.88**	**42.00**	**11.95**	**102.80**
10	**Paid up equity share capital**	**13.37**	**13.37**	**13.37**	**13.37**
	(Face Value of Equity Shares)	**10**	**10**	**10**	**10**
11	**Other Equity**	-	-	-	**650.38**
12	**Earning per share (of Rs. 10/- each)**				
	(a) Basic	**17.18**	**35.53**	**7.18**	**76.89**
	(b) Diluted	**17.18**	**35.53**	**7.18**	**76.89**

J.K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS FRN-004025N CHANDIGARH

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

VENUS®
Enjoy Innovations

Notes to the consolidated financial results: -

1. The above Consolidated Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 20th July 2026. The statutory auditors of the holding company have carried out limited review of the above Consolidated Financial Result for the quarter ended 30th June 2026, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.

2. The Consolidated Financial Results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. The parent company has a wholly owned subsidiary named Venus Pharma GmbH in Germany. Venus Pharma Kft is a step-down subsidiary of the parent company through Venus Pharma GmbH. The consolidated financial results include the results of both Venus Pharma GmbH and its step-down subsidiary Venus Pharma Kft.

4. The parent company's investment in its wholly owned subsidiary, Venus Pharma GmbH, remains pending for formal share allotment, as such allotment is not mandated under the applicable regulations in Germany. The Management considers the investment strategic in nature and, pursuant to the ongoing restructuring of European operations, has engaged a Germany-based financial consultancy firm to advise on the appropriate framework & mechanism.

5. Previous year / period figures have been regrouped/ reclassified wherever necessary.

6. The group has only one reportable segment namely "Pharmaceuticals"

For and on behalf of Board of Directors

for VENUS REMEDIES LIMITED

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

J. K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS FRN 004025N CHANDIGARH

Date: 20.07.2026

Pawan Chaudhary

(Chairman & Managing Director)

DIN: 00435503

Annexure A

Adoption of new set of Memorandum of Association ("MOA") of the Company as per Table-A of Schedule I of Companies Act, 2013, effecting the following modifications and amendments in the existing MOA:

i. Clause III(A) of MOA shall now be titled as 'The Objects to be pursued by the Company on its Incorporation are:' and the following clauses, be inserted in substitution for and to the entire exclusion of the existing clause III(A) of the MOA.

1. To carry on, in India or elsewhere in the world, the business of researching, discovering, developing, formulating, manufacturing, processing, refining, compounding, synthesising, extracting, cultivating, importing, exporting, buying, selling, marketing, distributing, supplying, storing, warehousing, packaging, repackaging, labelling, contract manufacturing, third-party manufacturing, loan licensing; and otherwise dealing in pharmaceutical, biopharmaceutical, biotechnology, healthcare and allied products, including active pharmaceutical ingredients, bulk drugs, intermediates, fine and specialty chemicals, formulations, biologics, biosimilars, vaccines, advanced-therapy, cell and gene therapy products, diagnostic products, medical devices, nutraceuticals, wellness products, veterinary products, cosmetics and personal-care products, and their raw materials, excipients, packaging materials, containers, closures and allied articles.
2. To undertake research, development, testing, analysis, quality assurance, quality control, validation, verification, qualification, calibration, certification, laboratory, regulatory, clinical-research and product-development activities and services in relation to pharmaceutical, biotechnology, healthcare and allied products, including pre-clinical and clinical studies, bioavailability and bioequivalence studies, pharmacovigilance, toxicology, stability studies, technology transfer, process optimisation, scale-up, regulatory submissions and product registrations; and to act as a contract research organisation, contract development and manufacturing organisation and contract manufacturer, subject to applicable laws.
3. To establish, acquire, own, lease, operate and maintain research and development centres, laboratories, pilot plants, manufacturing facilities, warehouses, diagnostic centres, healthcare and wellness facilities and other establishments necessary or incidental to the business of the Company; and to acquire, develop, licence, sublicense, assign, commercialise, transfer technology, franchise and otherwise exploit patents, trademarks, copyrights, know-how, software, databases, artificial-intelligence tools, digital platforms and other intellectual-property rights relating to the Company's business.
4. To establish, own, develop, operate and manage websites, mobile applications, digital platforms and e-commerce channels for the marketing, sale, distribution and delivery of pharmaceutical, healthcare and allied products and services; and to provide related order-management, customer-support, logistics-coordination, data-analytics, patient-support and allied services, subject to applicable laws.
5. To provide, establish, operate and manage, medical, diagnostic, preventive, therapeutic, rehabilitative, wellness, homecare, telehealth, teleconsultation, pharmacy-management and allied healthcare services and facilities, subject to obtaining all required registrations, approvals, licences and permissions under applicable laws.

ii. The title of the Clause III(B) was amended from "The Objects Incidental to the attainment of Main Objects are" to "Matters which are necessary for furtherance of the objects specified in Clause III (A) are".

1. To establish, acquire, lease, open, set up, own, maintain, operate, manage, relocate, transfer, close or discontinue factories, manufacturing facilities, processing units, laboratories, research and development centres, quality control and testing facilities, warehouses, cold chain facilities, distribution centres, depots, hospitals, healthcare institutions, offices, branches, agencies, subsidiaries and other establishments in India or abroad; to apply for, obtain, renew, modify, transfer, surrender or otherwise deal with all licences, registrations, approvals, permits, permissions, authorisations, certifications, accreditations, concessions and other statutory or regulatory approvals required for the Company or any such establishments; and to do all

VENUS REMEDIES LIMITED

VENUS®
Enjoy Innovations

such acts, deeds and things as may be necessary or incidental for carrying on the business of the Company in accordance with applicable laws.

2. To purchase, acquire, lease, exchange, hire, license, develop, construct, erect, maintain, improve, manage, operate, mortgage, charge, sell, transfer, assign or otherwise deal with any movable or immovable property, land, buildings, factories, warehouses, laboratories, offices, research centres, hospitals, clinics, manufacturing facilities, utilities, plants, machinery, equipment, vehicles and other assets required for carrying on the business of the Company.
3. To acquire, purchase, obtain, register, develop, improve, protect, maintain, renew, license, sublicense, assign, transfer, franchise, commercialize or otherwise deal in patents, patent rights, inventions, copyrights, trademarks, trade names, brands, industrial designs, geographical indications, know-how, trade secrets, confidential information, software, databases, technical information, formulations, manufacturing processes, proprietary technologies, intellectual property rights and similar rights.
4. To enter into any scheme of arrangement, amalgamation, merger, demerger or restructuring and to amalgamate, merge, demerge, or otherwise restructure with any person including firm, limited liability partnership, association of persons, body corporate, foreign company, subsidiaries, associates, joint ventures or any other entity.
5. To apply for, obtain, procure, renew, modify or otherwise deal with any licence, registration, permit, approval, consent, concession, exemption, privilege, authorisation, charter or other right from any Government, statutory, regulatory, local or other competent authority in India or elsewhere, and to take all such steps as may be necessary or expedient for enabling the Company to carry on, extend or efficiently conduct its business or to attain any of its objects, subject to applicable laws.
6. To enter into partnership, joint venture, alliance, or any arrangement, including arrangement of profit sharing, union of interest, reciprocal concessions or co-operation with any person, including firm, body corporate, other entities, whether incorporated or not, whether in India or abroad, carrying on or engaged in, or about to carry on or engage in, any business or transaction, which the Company is authorized to carry on or engage in, or which can be carried on in conjunction therewith or which is capable of being conducted so as to benefit the Company, directly or indirectly and to acquire individually or jointly the securities of any other body corporate having objects altogether, or in part similar, to these objects.
7. To undertake, sponsor, promote, finance or participate in scientific, technical, clinical, medical and commercial research, innovation, pilot projects, product development, technology development, technology transfer, incubation programmes and collaborative research with universities, research institutions, governments, industries or other organizations.
8. To enter into technical collaboration, joint ventures, strategic alliances, consortium arrangements, technology transfer agreements, manufacturing agreements, licensing arrangements, distribution agreements, franchise agreements, marketing arrangements or any other commercial arrangements with any individual, firm, company, institution, government, authority or body in India or abroad.
9. To appoint, engage or act as agents, representatives, brokers, distributors, stockists, franchisees, commission agents, clearing and forwarding agents, Del Credere Agent , consultants, contractors, advertiser, researcher, technicians, counsels and attorneys, service providers or otherwise for the conduct of the Company's business.
10. To establish, maintain and operate laboratories, analytical centres, quality assurance and quality control facilities, testing centres, validation facilities and calibration centres for carrying on the business of the Company.
11. To import, export, purchase, procure, sell, manufacture, process, formulate, package, repackage, label, relabel, transport, store, preserve, warehouse, stock and distribute raw materials, intermediates, active pharmaceutical ingredients (APIs), bulk drugs, formulations, finished goods, excipients, chemicals, biological materials, packaging materials, containers, closures, machinery, equipment, instruments, consumables and all other articles, materials, products and merchandise required for or incidental to the business of the Company.
12. To apply for, obtain, maintain, renew, surrender, transfer and comply with all licences, registrations, approvals, permissions, authorisations, certifications, accreditations, quotas and permits from any governmental, statutory, regulatory or other authority in India or elsewhere.

VENUS REMEDIES LIMITED

VENUS®
Enjoy Innovations

13. To establish, maintain and operate training centres and conduct educational, technical, professional and skill development programmes for employees, healthcare professionals, researchers, distributors, customers and other stakeholders.
14. To advertise, market, promote, publicize, exhibit, demonstrate, launch, sponsor, create awareness of, brand and commercialize the Company's products and services through seminars, conferences, exhibitions, trade fairs, scientific meetings, continuing medical education (CME) programmes, workshops, digital marketing, promotional campaigns and other lawful means; and to design, manufacture, procure, purchase, distribute or provide promotional materials, product literature, samples (where permitted), educational materials, branded merchandise, promotional merchandise, gifts, mementoes, souvenirs, complimentary articles, point-of-sale materials and other promotional items, subject always to the provisions of applicable laws, rules, regulations, industry codes and ethical standards.
15. To provide consultancy, advisory, technical, managerial, engineering, scientific, regulatory, information technology, quality assurance, project management and other professional services relating to the business of the Company.
16. To acquire, establish, promote or invest in any company, partnership, limited liability partnership, joint venture, trust, society or other entity carrying on activities similar to or ancillary to the business of the Company and to amalgamate, merge or enter into arrangements with such entities, subject to applicable law.
17. To raise funds by the issue of shares, debentures, bonds or other securities, and to borrow or secure the payment of money in such manner as the Company may deem fit, including by creating mortgages, charges, pledges, hypothecation or other security interests over the whole or any part of the Company's assets or properties, present or future, subject to the provisions of the Companies Act, 2013 and other applicable laws.

18. To invest or otherwise deal with the moneys of the Company, including surplus funds and funds not immediately required for the business, in such manner as may from time to time be determined by the Company and to invest in, acquire, subscribe for, purchase, hold, sell, redeem, transfer, assign, pledge, mortgage, endorse, discount, divest or otherwise deal in shares, stocks, debentures, bonds, Government securities, treasury bills, commercial papers, certificates of deposit, fixed deposits, units of mutual funds, exchange traded funds (ETFs), alternative investment funds (AIFs), hybrid securities, marketable securities, derivatives (where permissible), foreign securities and such other financial instruments, securities or investments of every kind or description, whether in India or abroad, for strategic, treasury or investment purposes, subject to the provisions of the Companies Act, 2013, the Foreign Exchange Management Act, 1999, the regulations of the Reserve Bank of India, the Securities and Exchange Board of India and other applicable laws.
19. To open, maintain and operate bank accounts of every description; avail banking facilities; issue, accept, endorse, discount and negotiate negotiable instruments; obtain guarantees, letters of credit, bank guarantees and other financial instruments for the purposes of the Company's business.
20. To borrow, raise or receive money or avail fund based or non-fund based facilities from any bank, financial institution, body corporate or any other person, whether in India or abroad, at interest or otherwise, in such a manner as the Company may think fit, including by way of issuance of securities, with or without any security or charge or encumbrance on the Company's properties.
21. Without prejudice to the generality of the foregoing provisions, to mortgage, hypothecate, pledge or otherwise create any charge, lien, encumbrance or security interest over the whole or any part of the Company's present or future property, assets, undertakings, rights, interests, titles, revenues, profits or uncalled capital, or to transfer or convey the same absolutely or in trust, and to confer upon the mortgagee, charge-holder, pledgee or other secured creditor the power to sell, assign, exchange, lease, licence, create easements, improve, manage, develop, realize, exploit or otherwise deal with or dispose of the whole or any part of the Company's properties, assets, investments, undertakings, rights, concessions and effects in such manner as the Company may deem fit, and to guarantee the performance of contracts, obligations or liabilities of every kind, subject to applicable laws.
22. To insure the Company's assets, properties, business, employees, products, liabilities, directors, officers and other risks with any insurance company or insurer and to recover, receive and deal with insurance claims.

VENUS REMEDIES LIMITED

VENUS®
Enjoy Innovations

23. To employ, appoint, engage, remunerate, train and retain directors, officers, employees, scientists, medical professionals, consultants, advisors, technicians, researchers and other personnel and to establish provident funds, gratuity funds, pension schemes, welfare funds, incentive schemes, stock option schemes and other benefit programmes.
24. To institute, defend, compromise, settle or otherwise deal with any legal, arbitration, mediation or other proceedings for the protection or enforcement of the rights, properties, interests and business of the Company.
25. To apply for and participate in any tender, bidding process or registration with Government bodies for the supply of medicines or to otherwise acquire any Government contracts or concessions in relation to the supply of medicines and to undertake and fulfil requirements on being successfully awarded supply contracts.
26. To make donations, grants, subscriptions or contributions for scientific, educational, charitable, social, environmental, healthcare, community development or corporate social responsibility purposes, subject to applicable laws.
27. To create, establish and maintain reserve funds, sinking funds, insurance funds, depreciation funds, replacement funds, repair and maintenance funds or any other special funds as may be considered necessary or expedient for the depreciation, repair, renewal, replacement, extension, improvement, maintenance or preservation of the assets, properties or business of the Company, or as may be required or authorised under applicable laws.
28. To promote the welfare of the present and former employees, directors, officers and other personnel of the Company and their families by establishing, maintaining or contributing to housing, educational, medical, recreational and welfare facilities; and by granting pensions, gratuities, allowances, bonuses, compensation or other benefits, and by establishing or contributing to provident, gratuity, superannuation, pension, welfare or other benefit funds, subject to applicable laws.
29. To guarantee or secure the performance of contracts or obligations, or the payment of money, dividends or interest on any shares, stocks, debentures or other securities of any person, company or other body corporate, or the subscription thereof, where such guarantee is considered likely, directly or indirectly, to further the objects or interests of the Company or its shareholders, subject to applicable laws.
30. To lend or advance money, with or without security, to such persons, companies or other entities, and on such terms as the Company may deem fit, including employees, customers, suppliers and others having business dealings with the Company, and to guarantee or secure the performance of contracts or obligations of any such persons or entities; provided that nothing herein shall authorise the Company to carry on the business of banking or any other activity requiring registration or licence under applicable law.
31. To carry on any other business, activity or undertaking which may, in the opinion of the Company, be conveniently or advantageously carried on in connection with, or ancillary or incidental to, the business which the Company is authorised to carry on, or which is calculated directly or indirectly to enhance the value of, render profitable, support, facilitate or promote the Company's business, assets, properties or rights.
32. To undertake, promote and implement environmental, social and governance (ESG) initiatives, sustainability programmes, renewable energy, energy efficiency, waste management, circular economy, carbon credits, renewable energy certificates, green credits and other environmental initiatives, and to comply with applicable sustainability standards, ESG reporting requirements and other environmental frameworks.
33. To enter into technology transfer, licensing, sub-licensing, in-licensing, out-licensing, co-development, co-marketing, co-promotion, commercialization of intellectual property, contract manufacturing (CMO/CDMO), contract research (CRO) and other strategic, technical, commercial or business collaborations, alliances and arrangements in India or abroad.
34. To undertake warehousing, cold-chain logistics, fulfilment, serialization, track-and-trace services, regulatory affairs, pharmacovigilance, medical writing, dossier preparation, regulatory submissions and other supply chain, regulatory and allied support services for the Company's business and for third parties.
35. To establish, acquire and operate overseas subsidiaries, including step-down subsidiaries, branches, representative offices and other international operations, and to raise capital through domestic or international equity, debt or other permissible instruments in accordance with applicable laws.
36. To undertake all such lawful acts, deeds and things as are incidental or conducive to the attainment of the foregoing Main Objects or any of them.

VENUS REMEDIES LIMITED